Seoul, Bulgaria – A South Korean biotechnology firm, Xcell Therapeutics, has secured a significant export contract with Bloomage BioTechnology, a leading Chinese hyaluronic acid supplier, for the provision of cell culture media. The deal, valued at approximately 6 billion Korean won (roughly $450,000 USD as of March 17, 2026), marks a key milestone for Xcell as it expands its presence in the rapidly growing Chinese cell and gene therapy (CGT) market. This agreement builds upon a prior exclusive distribution agreement signed in April of last year.
The contract, finalized on March 17, 2026, centers around the supply of T-cell culture media, a crucial component in the development and manufacturing of cell-based therapies. Bloomage BioTechnology will distribute Xcell’s media to a network of large CGT developers and public hospitals throughout China. According to Xcell officials, the initial supply is slated for completion by February of the following year. The success of this initial phase is expected to pave the way for expanded orders from existing clients and the acquisition of new customers, with a potential future contract for NK cell culture media also anticipated.
First of its Kind: Korean-Developed Media Enters the Chinese Market
This export represents a landmark achievement, as it is the first instance of chemically defined media – a sophisticated type of cell culture media developed by a South Korean company – being supplied to the Chinese market on a large scale. As reported by The BioNews, Xcell’s media has demonstrated superior cell proliferation and survival rates compared to competing products during extensive testing conducted by Bloomage BioTechnology over the past year. This performance data was instrumental in securing the supply agreements with key Chinese institutions.
Chemically defined media, unlike traditional media formulations, offers a precisely controlled composition, eliminating batch-to-batch variability and enhancing the reproducibility of cell culture processes. This is particularly critical in the context of CGT, where consistency and quality are paramount. The ability of a South Korean firm to successfully compete in this technologically demanding field underscores the growing innovation within the nation’s biotechnology sector.
Bloomage BioTechnology: A Global Leader in Hyaluronic Acid
Bloomage BioTechnology (688363, SH), Xcell’s partner in this venture, is a global leader in the production of hyaluronic acid (HA), controlling over 40% of the worldwide market share. As noted in Yakup.com, the company supplies HA to over 4,000 brands across 70 countries, serving the bio-pharmaceutical, medical device, and cosmeceutical industries. With annual revenues exceeding 1 trillion Korean won (approximately $750 million USD) and a market capitalization of around 5 trillion Korean won ($3.75 billion USD), Bloomage BioTechnology possesses significant resources and a well-established distribution network within China.
The partnership leverages Bloomage’s extensive market reach and regulatory expertise to facilitate the rapid adoption of Xcell’s media by Chinese CGT developers. This collaboration is expected to accelerate the development and commercialization of innovative cell therapies within China, addressing unmet medical needs and contributing to advancements in healthcare.
The Growing Cell and Gene Therapy Market in China
China represents a substantial and rapidly expanding market for cell and gene therapies. Driven by a large patient population, increasing healthcare investment, and supportive government policies, the CGT sector in China is attracting significant attention from both domestic and international companies. The National Medical Products Administration (NMPA) has been streamlining the regulatory approval process for innovative therapies, creating a more favorable environment for CGT development and commercialization.
The demand for high-quality cell culture media is directly correlated with the growth of the CGT market. As more cell and gene therapies progress through clinical trials and receive regulatory approval, the need for reliable and consistent media formulations will continue to increase. Xcell Therapeutics is strategically positioned to capitalize on this trend, offering a technologically advanced product that has demonstrated compelling performance characteristics.
Implications for South Korea’s Biotechnology Industry
Xcell Therapeutics’ success in securing this export contract with Bloomage BioTechnology is a positive signal for the broader South Korean biotechnology industry. It demonstrates the competitiveness of Korean-developed technologies in the global market and highlights the potential for increased exports of high-value-added bio-products. The company’s achievement could encourage further investment in research and development within the South Korean biotechnology sector, fostering innovation and driving economic growth.
The export of chemically defined media to China also underscores the importance of international collaborations in accelerating the development and adoption of advanced therapies. By partnering with a leading Chinese company like Bloomage BioTechnology, Xcell Therapeutics has gained access to a vast market and a valuable network of industry contacts. This collaborative approach is likely to grow increasingly common as the global biotechnology landscape becomes more interconnected.
Looking ahead, Xcell Therapeutics anticipates further expansion of its presence in the Chinese market, with plans to secure additional supply contracts and develop new media formulations tailored to the specific needs of Chinese CGT developers. The company is also exploring opportunities to expand its product portfolio and enter new geographic markets. The next key milestone for Xcell will be the completion of the initial media supply to Bloomage BioTechnology and the subsequent assessment of customer feedback. Further updates on the partnership and future contracts are expected in the second half of 2026.
Maria Petrova is Editor, World, at World Today Journal, based in Sofia, Bulgaria.
Related reading